As with drug-eluting stents （DES）, biomacromolecule-eluting stents can deliver biologically active agents such as nucleic acid, antibody, enzyme and cell factor. Biological active agents can selectively act at specific target location through molecular mechanism of coronary artery restenosis. This seems to be a promising treatment strategy for preventing in-stent restenosis （ISR） while simultaneously reducing the risk of stent thrombosis. This article reviews recent developments in biomacromolecule-eluting stents.